| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIOGEN | 18 | 54 | +6,34 % | ||
| KALVISTA PHARMACEUTICALS | 16 | 1 | +37,74 % | ||
| REGENERON PHARMACEUTICALS | 14 | 22 | -6,35 % | ||
| AGIOS | 6 | 8 | +13,21 % | ||
| IONIS PHARMACEUTICALS | 5 | - | +2,38 % | ||
| BIONTECH | 4 | 13 | -0,17 % | ||
| APELLIS PHARMACEUTICALS | 4 | 4 | -0,74 % | ||
| GH RESEARCH | 4 | - | +1,78 % | ||
| AMGEN | 3 | 27 | -0,53 % | ||
| RELAY THERAPEUTICS | 3 | 3 | 0,00 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03:05 | Mesoblast shares: Cash burn falls and Ryoncil sales climb | 1 | The Motley Fool Australia | ||
| 03:00 | Mesoblast Limited: Mesoblast Reports Ryoncil Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million | 1 | GlobeNewswire (USA) | ||
| 02:27 | Why Biogen Stock Was a Winner on Wednesday | 3 | The Motley Fool | ||
| 01:27 | Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday | 1 | The Motley Fool | ||
| 00:56 | MESOBLAST LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 00:42 | Oppenheimer raises Ionis Pharmaceuticals price target on guidance | 1 | Investing.com | ||
| 00:26 | Roivant Sciences Ltd. (ROIV): David Einhorn Trims Stake | 1 | Insider Monkey | ||
| Mi | $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today | 3 | Benzinga.com | ||
| Mi | Pacira BioSciences Q1 2026 Earnings Preview | 1 | Seeking Alpha | ||
| Mi | Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know | 1 | Zacks | ||
| Mi | Truist cuts Regeneron stock price target on FDA approval delay | 4 | Investing.com | ||
| Mi | Stifel raises Ionis Pharmaceuticals price target on sHTG opportunity | 3 | Investing.com | ||
| Mi | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 | 1 | GlobeNewswire (USA) | ||
| Mi | Autolus Therapeutics plc - 8-K, Current Report | - | SEC Filings | ||
| Mi | Autolus to cut about 13% of workforce in cost reduction initiative | 2 | Seeking Alpha | ||
| Mi | Ultragenyx vor Quartalsbericht: Wichtiger Test für die Gentherapie-Pipeline | 2 | Investing.com Deutsch | ||
| Mi | Relay Therapeutics vor Quartalszahlen: Lässt sich der klinische Erfolg in Kurspotenzial ummünzen? | 1 | Investing.com Deutsch | ||
| Mi | Neurocrine announces tardive dyskinesia scale threshold study | 4 | Investing.com | ||
| Mi | Olema Pharmaceuticals appoints Prakash Raman to board | 1 | Investing.com | ||
| Mi | DRI Healthcare Trust Comments on Proposed Acquisition of KalVista Therapeutics, Inc. | 2 | CNW |